Pfizer Stops Sales on Exubera
October 29, 2007
After less than two years after introducing the new inhaled insulin drug Exubera, Pfizer announced it would stop selling the product. Despite Pfizer’s heavy promotion, Exubera’s sales were less than anticipated, with prescriptions amounting to less than 1 percent of the insulin market. Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive failures in the history of the pharmaceutical industry.Several companies, including Eli Lilly, are investing in expensive programs to develop inhaled insulin. But Pfizer said it would not try to develop a replacement for Exubera, ending its inhaled insulin research after more than a decade of work.
Click here for NY Time’s full article.
Comments
Got something to say?
Powered by WordPress
